Hazte socio de la SAMFyC

Última publicación SAMFyC: Actualización en MF y APS

 

AULA VIRTUAL SAMFyC

Aula de formación virtual de SAMFyC

SAMFyC CONGRESOS

Historico de Comunicaciones
presentadas a los Congresos
Andaluces de MFyC (SAMFyC), desde 2008.


* * * * * * * * * * * * * * * * * * * * * * * * *

Información Socios

Ofertas de Trabajo
Ofertas de Trabajo SOCIOS SAMFYC

¡Actualiza tus datos!
Actualiza tus datos

 

Buscador de Contenidos

Sociedades Federadas

Medicina Familiar y Comunitaria

Sociedades Científicas de Medicina Familiar y Comunitaria

Enlaces de Interés

Consulte Nuestros Enlaces.
Enlaces de Interés

Acceso Socios



Buscador de publicaciones externas y alertas bibliográficas

Diciembre 2014 PDF Imprimir E-mail
Lunes, 05 de Enero de 2015 00:00

<< Volver

 

SELECCIÓN DE REFERENCIAS BIBLIOGRÁFICAS DE LO PUBLICADO EN RELACIÓN CON ATENCIÓN PRIMARIA

Selección realizada por Antonio Manteca González

 

ANNALS OF INTERNAL MEDICINE 

 

LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:819-826 [M,III]

25200125             R/C

USO DE ASPIRINA EN DOSIS BAJA PARA LA PREVENCIÓN DE LA MORBILIDAD Y MORTALIDAD EN LA PREECLAMPSIA: DECLARACIÓN DE RECOMENDACIÓN DEL USPSTF

 

Isakov A, Jamison A, Miles W, Ribner B. Safe management of patients with serious communicable diseases: recent experience with Ebola virus. Ann Intern Med 2014;161:829-830 [AO,I]

25244492

MANEJO SEGURO DE LOS PACIENTES CON ENFERMEDADES TRANSMISIBLES GRAVES: EXPERIENCIA RECIENTE CON EL VIRUS DEL ÉBOLA

 

Zakher B, Cantor AG, Pappas M, Daeges M, Nelson HD. Screening for gonorrhea and Chlamydia: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2014;161:884-893 [M,II]

25244000             R/C

CRIBAJE DE GONORREA Y CLAMIDIA: REVISIÓN SISTEMÁTICA PARA EL USPSTF

 

LeFevre ML; U.S. Preventive Services Task Force. Behavioral counseling interventions to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:894-901 [M,II]

25244227             R/C

INTERVENCIONES DE CONSEJO CONDUCTUAL PARA PREVENIR LAS INFECCIONES DE TRANSMISIÓN SEXUAL: DECLARACIÓN DE RECOMENDACIÓN DEL USPSTF

 

LeFevre ML; U.S. Preventive Services Task Force. Screening for Chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:902-910 [M,II]

25243785             R/C

CRIBAJE DE GONORREA Y CLAMIDIA: DECLARACIÓN DE RECOMENDACIÓN DEL USPSTF

 

ARCHIVOS DE BRONCONEUMOLOGIA 

 

Lopez-Campos JL, Lopez-Ramirez C, Marquez-Martín E. Agudizaciones de la enfermedad pulmonar obstructiva crónica y condensación radiológica: tres preguntas controvertidas. Arch Bronconeumol 2014;50:503-504 [AO,I]

25457938

AGUDIZACIONES DE LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA Y CONDENSACIÓN RADIOLÓGICA: TRES PREGUNTAS CONTROVERTIDAS

 

Boixeda R, Bacca S, Elias L, Capdevila JA, Vilà X, Mauri M, et al. La neumonía como comorbilidad en la enfermedad pulmonar obstructiva crónica (EPOC). Arch Bronconeumol 2014;50:514-520 [S,I]

25443591             R/C

LA NEUMONÍA COMO COMORBILIDAD EN LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA (EPOC)

 

González N, Troncoso MF, Gómez T. Terapias ventilatorias domiciliarias en el síndrome de apnea-hipopnea del sueño. Arch Bronconeumol 2014;50:528-534 [R,I]

25059585             R/C

TERAPIAS VENTILATORIAS DOMICILIARIAS EN EL SÍNDROME DE APNEA-HIPOPNEA DEL SUEÑO

 

ARTHRITIS AND RHEUMATOLOGY 

 

Yoo JJ, Cho NH, Lim SH, Kim HA. Relationships between body mass index, fat mass, muscle mass, and musculoskeletal pain in community residents. Arthritis Rheumatol 2014;66:3511-3520 [T,I]

25185757             R/C

RELACIONES ENTRE IMC, MASA GRASA, MASA MUSCULAR Y DOLOR OSTEOMUSCULAR EN RESIDENTES EN LA COMUNIDAD

 

ATENCION PRIMARIA 

 

Mora RM. Conciliación y prescripción electrónica. Aten Primaria 2014;46:529-530 [AO,I]

25458923

CONCILIACIÓN Y PRESCRIPCIÓN ELECTRÓNICA

 

López-Torres J, Basora J, Orozco D, Bellón JÁ. Mapa bibliométrico de la investigación realizada en atención primaria en España durante el periodo 2008-2012. Aten Primaria 2014;46:541-548 [T,I]

24811538             R/C

MAPA BIBLIOMÉTRICO DE LA INVESTIGACIÓN REALIZADA EN ATENCIÓN PRIMARIA EN ESPAÑA DURANTE EL PERIODO 2008-2012

 

Gancedo-García A, Gutiérrez-Antezana AF, González-García P, Salinas-Herrero S, Prieto-Merino D, Suárez-Gil P. Efectividad de una intervención educativa breve en pacientes con insomnio en atención primaria. Aten Primaria 2014;46:549-557 [EC,I]

24986634             R/C

EFECTIVIDAD DE UNA INTERVENCIÓN EDUCATIVA BREVE EN PACIENTES CON INSOMNIO EN ATENCIÓN PRIMARIA

 

Maestre-Miquel C, Martínez D, Polonio B, Astasio P, Santos J, Regidor E. Desigualdades en inactividad física según el nivel de estudios en España, en 1987 y 2007. Aten Primaria 2014;46:565-572 [T,I]

24863857             R/C

DESIGUALDADES EN INACTIVIDAD FÍSICA SEGÚN EL NIVEL DE ESTUDIOS EN ESPAÑA, EN 1987 Y 2007

 

Catalá-López F, Tobías A, Roqué M. Conceptos básicos del metaanálisis en red. Aten Primaria 2014;46:573-581 [R,I]

                               R/C

CONCEPTOS BÁSICOS DEL METAANÁLISIS EN RED

 

BRITISH JOURNAL OF PSYCHIATRY 

 

Savic C, Belkic K. Why are job stressors relevant for psychiatry? Br J Psychiatry 2014;205:425-427 [AO,I]

25452599             R/C

¿POR QUÉ SON RELEVANTES EN PSIQUIATRÍA LOS ESTRESORES LABORALES?

 

Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry 2014;205:436-442 [M,II]

25452601             R/C

INTERVENCIONES NO FARMACOLÓGICAS PARA LA AGITACIÓN EN LA DEMENCIA: REVISIÓN SISTEMÁTICA DE ENSAYOS CONTROLADOS ALEATORIZADOS

 

Fountoulakis KN, Kawohl W, Theodorakis PN, Kerkhof AJ, Navickas A, Höschl C, et al. Relationship of suicide rates to economic variables in Europe: 2000-2011. Br J Psychiatry 2014;205:486-496 [T,II]

25359926             R/C

RELACIÓN DE TASAS DE SUICIDIO CON VARIABLES ECONÓMICAS EN EUROPA: 2000-2011

 

BRITISH MEDICAL JOURNAL 

 

Wood LN, Anger JT. Urinary incontinence in women. BMJ 2014;349:g4531 [R,I]

25225003             R/C

INCONTINENCIA URINARIA EN MUJERES

 

Neal RD, Hamilton W, Rogers TK. Lung cancer. BMJ 2014;349:g6560

[R,I]

25376443

CÁNCER DE PULMÓN

 

Yang JH, Hahn JY, Song YB, Choi SH, Choi JH, Lee SH, et al. Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study. BMJ 2014;349:g6650 [S,I]

25398372             R/C

BLOQUEANTES DEL RECEPTOR DE ANGIOTENSINA EN PACIENTES CON INFARTO DE MIOCARDIO CON ELEVACIÓN DEL SEGMENTO ST CON FUNCIÓN SISTÓLICA VENTRICULAR PRESERVADA: ESTUDIO DE COHORTE PROSPECTIVO

 

Eccles S, Pincus C, Higgins B, Woodhead M; Guideline Development Group. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ 2014;349:g6722

[M,II]

25471702

DIAGNÓSTICO Y TRATAMIENTO DE NEUMONÍA ADQUIRIDA EN LA COMUNIDAD Y ADQUIRIDA EN EL HOSPITAL EN ADULTOS: RESUMEN DE LA GUÍA NICE

 

Hole B, Whittlestone T, Tomson C. Investigating asymptomatic invisible haematuria. BMJ 2014;349:g6768

[R,I]

25404006

INVESTIGAR LA HEMATURIA OCULTA ASINTOMÁTICA

 

Sumner P, Vivian-Griffiths S, Boivin J, Williams A, Venetis CA, Davies A, et al. The association between exaggeration in health related science news and academic press releases: retrospective observational study. BMJ 2014;349:g7015 [T,I]

25498121             R/C

ASOCIACIÓN ENTRE EXAGERACIÓN EN LAS NOTICIAS CIENTÍFICAS RELACIONADAS CON LA SALUD Y LOS COMUNICADOS DE PRENSA ACADÉMICOS

 

Chew M, Brizzell C, Abbasi K, Godlee F. Medical journals and industry ties. BMJ 2014;349:g7197 [AO,I]

25432164

REVISTAS MÉDICAS Y LAZOS CON LA INDUSTRIA

 

Neville R, Austin S. The King Canute GP appointment system. BMJ 2014;349:g7228 [QE,I]

25500115

SISTEMA DE CITAS DE MEDICINA GENERAL DEL REY CANUTO

 

Brunet M. Target diagnosis rates in primary care are misleading and unethical. BMJ 2014;349:g7235

[R,I]

25467381

LOS OBJETIVOS DE TASAS DIAGNÓSTICAS EN ATENCIÓN PRIMARIA SON ENGAÑOSOS Y POCO ÉTICOS

 

Meerman R, Brown AJ. When somebody loses weight, where does the fat go? BMJ 2014;349:g7257 [T,I]

25516540

CUANDO ALGUIEN PIERDE PESO ¿A DÓNDE VA LA GRASA?

 

Arroll B, Alrutz S, Moyes S. An exploration of the basis for patient complaints about the oldness of magazines in practice waiting rooms: cohort study. BMJ 2014;349:g7262 [S,I]

25500116             R/C

EXPLORACIÓN DE LA BASE DE LAS QUEJAS DE LOS PACIENTES SOBRE LA ANTIGÜEDAD DE LAS REVISTAS EN LAS SALAS DE ESPERA DE LAS CONSULTAS: ESTUDIO DE COHORTE

 

Page VJ. Delirium on the intensive care unit. BMJ 2014;349:g7265 [AO,I]

SÍNDROME CONFUSIONAL EN LA UNIDAD DE CUIDADOS INTENSIVOS

 

Beeching NJ, Fenech M, Houlihan CF. Ebola virus disease. BMJ 2014;349:g7348

[R,II]

25497512

ENFERMEDAD POR EL VIRUS DEL ÉBOLA

 

Koeck C. Imbalance of power between patients and doctors. BMJ 2014;349:g7485 [AO,I]

25512331

DESEQUILIBRIO DE PODER ENTRE PACIENTES Y MÉDICOS

 

Singleton N, Strang J. What would an evidence based drug policy be like? BMJ 2014;349:g7493 [AO,I]

25492041

¿CÓMO DEBERÍA SER UNA POLÍTICA FARMACOLÓGICA BASADA EN LA EVIDENCIA?

 

Wilkinson R, Pickett K. How 21st century capitalism is failing us. BMJ 2014; 349:g7516 [AO,I]

25512393

CÓMO NOS ESTÁ DEFRAUDANOD EL CAPITALISMO EN EL SIGLO 21

 

CANADIAN MEDICAL ASSOCIATION JOURNAL 

 

Poonai N, Bhullar G, Lin K, Papini A, Mainprize D, Howard J, et al. Oral administration of morphine versus ibuprofen to manage postfracture pain in children: a randomized trial. CMAJ 2014;186:1358-1363 [EC,I]

25349008             R/C

ADMINISTRACIÓN ORAL DE MORFINA FRENTE A IBUPROFENO PARA TRATAR EL DOLOR POSTFRACTURA EN NIÑOS: ENSAYO ALEATORIZADO

 

Frank C, Weir E. Deprescribing for older patients. CMAJ 2014;186:1369-1376 [AO,II]

25183716

DEPRESCRIBIR EN ANCIANOS

 

Ponka D, Dickinson J. Screening with the Pap test. CMAJ 2014;186:1394 [AO,I]

25384655

CRIBAJE CON LA PRUEBA DE PAPANICOLAU

 

Padwal RS, Rabkin S, Khan N. Assessment and management of resistant hypertension. CMAJ 2014;186:E689-E697 [R,I]

25135921

VALORACIÓN Y MANEJO DE LA HIPERTENSIÓN RESISTENTE

 

CIRCULATION 

 

January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130:2071-2104 [M,III]

24682348

GUÍA AHA/ACC/HRS 2014 PARA EL MANEJO DE PACIENTES CON FIBRILACIÓN AURICULAR: RESUMEN EJECUTIVO: INFORME DEL ACC/GRUPO DE TRABAJO SOBRE GUÍAS DE PRÁCTICA CLÍNICA DE LA AHA/HRS

 

January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130:e199-e267 [M,III]

24682347

GUÍA AHA/ACC/HRS 2014 PARA EL MANEJO DE PACIENTES CON FIBRILACIÓN AURICULAR: INFORME DEL ACC/GRUPO DE TRABAJO SOBRE GUÍAS DE PRÁCTICA CLÍNICA DE LA AHA/HRS

 

Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Li W, Johnson J, et al. Body mass index and the risk of all-cause mortality among patients with type 2 diabetes. Circulation 2014 [Epub ahead of print]

[S,II]

25378546             R/C

IMC Y RIESGO DE MORTALIDAD POR CUALQUIER CAUSA ENTRE PACIENTES CON DIABETES TIPO 2

 

Carnethon MR. Diabetes in the absence of obesity: a risky condition. Circulation 2014 [Epub ahead of print]

[AO,I]

25378545             R/C

DIABETES EN AUSENCIA DE OBESIDAD: ESTADO DE RIESGO

 

DIABETES CARE 

 

Cefalu WT, Petersen MP, Ratner RE. The alarming and rising costs of diabetes and prediabetes: a call for action! Diabetes Care 2014;37:3137-3138 [AO,I]

25414386

LOS COSTES EN ASCENSO Y ALARMANTES DE LA DIABETES Y LA PREDIABETES: ¡LLAMAMIENTO  A LA ACCIÓN!

 

Spijkerman AM, van der A DL, Nilsson PM, Ardanaz E, Gavrila D, Agudo A, et al; InterAct Consortium. Smoking and long-term risk of type 2 diabetes: the EPIC-InterAct study in European populations. Diabetes Care 2014;37:3164-3171 [S,II]

25336749             R/C

TABAQUISMO Y RIESGO DE DIABETES TIPO 2 A LARGO PLAZO : ESTUDIO EPIC-INTERACT EN POBLACIONES EUROPEAS

 

Dall TM, Yang W, Halder P, Pang B, Massoudi M, Wintfeld N, et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care 2014;37:3172-3179 [T,II]

25414388             R/C

LA CARGA ECONÓMICA DE LOS NIVELES ELEVADOS DE AZÚCAR EN SANGRE EN 2012: DIABETES DIAGNOSTICADA Y SIN DIAGNOSTICAR, DIABETES MELLITUS GESTACIONAL Y PREDIABETES

 

Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E, et al; EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37:3235-3243 [EC,II]

25193531             R/C

NUEVA INSULINA GLARGINA 300 UU/ML FRENTE A LA GLARGINA 100 UU/ML EN PERSONAS CON DIABETES TIPO 2 QUE USAN AGENTES ORALES E INSULINA BASAL: CONTROL DE GLUCOSA E JHIPOGLUCEMIA EN UN ENSAYO CONTROLADO ALEATORIZADO (EDITION 2)

 

Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic ß-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014;37:3270-3278 [EC,I]

25249651             R/C

LIRAGLUTIDA Y  PRESERVACIÓN DE LA FUNCIÓN DE LA CÉLULA BETA PANCREÁTICA EN LA DIABETES TIPO 2 TEMPRANA: ENSAYO LIBRA

 

Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014;37:3309-3316 [EC,I]

25249652             R/C

TRATAMIENTO DE PÉRDIDA DE PESO EN LA DIABETES TIPO 2: EFECTOS DE LA FENTERMINA Y EL TOPIRAMATO DE LIBERACIÓN PROLONGADA

 

Viana LV, Gross JL, Azevedo MJ. Dietary intervention in patients with gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials on maternal and newborn outcomes. Diabetes Care 2014;37:3345-3355 [M,II]

25414390             R/C

INTERVENCIÓN DIETÉTICA EN PACIENTES CON DIABETES MELLITUS GESTACIONAL: REVISIÓN SISTEMÁTICA Y METAANÁLISIS DE ENSAYOS CLÍNICOS ALEATORIZADOS SOBRE LOS RESULTADOS MATERNOS Y DE LOS RECIÉN NACIDOS

 

DRUGS 

 

Luke JJ, Ott PA, Shapiro GI. The biology and clinical development of MEK inhibitors for cancer. Drugs 2014;74:2111-2128 [R,I]

25414119             R/C

BIOLOGÍA Y DESARROLLO CLÍNICO DE LOS INHIBIDORES MEK PARA EL CÁNCER

 

Carris NW, Taylor JR, Gums JG. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations. Drugs 2014;74:2141-2152. [R,I]

25414121             R/C

COMBINAR AGONISTAS DE LOS RECEPTORES GLP-1 E INSULINA BASAL: EVIDENCIA DE LOS ESTUDIOS Y CONSIDERACIONES PRÁCTICAS

 

Scott LJ. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes. Drugs 2014;74:2153-2160 [R,I]

25352391             R/C

RIFAXIMINA: REVISIÓN DE SU USO PARA REDUCIR LAS RECURRENCIAS DE LOS EPISODIOS DE ENCEFALOPATÍA HEPÁTICA MANIFIESTA

 

Scott LJ. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus. Drugs 2014;74:2161-2174 [R,I]

25367717             R/C

LIRAGLUTIDA: REVISIÓN DE SU USO EN PACIENTES ADULTOS CON DIABETES MELLITUS TIPO 2

 

Frampton JE. Pramipexole extended-release: a review of its use in patients with Parkinson's disease. Drugs 2014;74:2175-2190 [R,I]

25385556             R/C

PRAMIPEXOL DE LIBERACIÓN PROLONGADA: REVISIÓN DE SU USO EN PACIENTES CON ENFERMEDAD DE PARKINSON

 

Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs 2014;74:2191-2209 [R,I]

25389049             R/C

DAPAGLIFLOZINA: REVISIÓN DE SU USO EN PACIENTES CON DIABETES TIPO 2

 

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA 

 

García-San Miguel L, Cobo J, Martínez JA, Arnau JM, Murillas J, Peña C, et al; el Grupo REIPI. La «intervención del tercer día»: análisis de los factores asociados al seguimiento de recomendaciones sobre la prescripción de antibióticos. Enferm Infecc Microbiol Clin 2014;32:654-661 [EC,II]

24813928             R/C

LA «INTERVENCIÓN DEL TERCER DÍA»: ANÁLISIS DE LOS FACTORES ASOCIADOS AL SEGUIMIENTO DE RECOMENDACIONES SOBRE LA PRESCRIPCIÓN DE ANTIBIÓTICOS

 

Hernández-Navarrete MJ, Celorrio-Pascual JM, Lapresta C, Solano VM. Fundamentos de antisepsia, desinfección y esterilización. Enferm Infecc Microbiol Clin 2014;32:681-688 [R,II]

25023372             R/C

FUNDAMENTOS DE ANTISEPSIA, DESINFECCIÓN Y ESTERILIZACIÓN

 

EUROPEAN HEART JOURNAL 

 

Kolandaivelu K, Leiden BB, O'Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J 2014;35:3267-3276 [R,I]

25265973             R/C

FALTA DE CUMPLIMIENTO DE LA MEDICACIÓN CARDIOVASCULAR

 

Banegas JR, Ruilope LM, de la Sierra A, de la Cruz JJ, Gorostidi M, Segura J, et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J 2014;35:3304-3312 [T,II]

24497346             R/C

ALTA PREVALENCIA OCULTA DE LA HIPERTENSIÓN SIN CONTROLAR EN PERSONAS CON HIPERTENSIÓN TRATADA

 

FAMILY PRACTICE 

 

Burton C. Can we explain medically unexplained symptoms? Fam Pract 2014;31:623-624 [AO,I]

25415972

¿PODEMOS EXPLICAR LOS SÍNTOMAS NO EXPLICADOS?

 

Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract 2014;31:625-630 [M,II]

25192903             R/C

ESTRATEGIAS DE RETIRADA DE LOS INHIBIDORES DE LA BOMBA DE PROTONES: REVISIÓN SISTEMÁTICA

 

Glass GE, Tzafetta K. Bell's palsy: a summary of current evidence and referral algorithm. Fam Pract 2014;31:631-642 [R,I]

25208543             R/C

PARÁLISIS DE BELL: RESUMEN DE LA EVIDENCIA ACTUAL Y ALGORITMO DE DERIVACIÓN

 

Booth HP, Prevost TA, Wright AJ, Gulliford MC. Effectiveness of behavioural weight loss interventions delivered in a primary care setting: a systematic review and meta-analysis. Fam Pract 2014;31:643-653 [M,II]

25298510             R/C

EFECTIVIDAD DE LAS INTERVENCIONES CONDUCTUALES PARA LA PÉRDIDA DE PESO EN UN DISPOSITIVO DE ATENCIÓN PRIMARIA: REVISIÓN SISTEMÁTICA Y METAANÁLISIS

 

Doos L, Roberts EO, Corp N, Kadam UT. Multi-drug therapy in chronic condition multimorbidity: a systematic review. Fam Pract 2014;31:654-663 [M,II]

25192902             R/C

TRATAMIENTO PLURIFARMACOLÓGICO EN EL ESTADO DE PLURIMORBILIDAD CRÓNICA: REVISIÓN SISTEMÁTICA

 

Clarey J, Lasserson D, Levi C, Parsons M, Dewey H, Barber PA, et al. Absolute cardiovascular risk and GP decision making in TIA and minor stroke. Fam Pract 2014;31:664-669 [S,II]

25208544             R/C

RIESGO CARDIOVASCULAR ABSOLUTO Y TOMA DE DECISIONES DEL MÉDICO GENERAL EN EL AIT Y EL ICTUS MENOR

 

Schieber AC, Delpierre C, Lepage B, Afrite A, Pascal J, Cases C, et al; INTERMEDE group. Do gender differences affect the doctor-patient interaction during consultations in general practice? Results from the INTERMEDE study. Fam Pract 2014;31:706-713 [T,II]

25214508             R/C

¿AFECTAN LAS DIFERENCIAS DE SEXO A LA INTERACCIÓN MÉDICO-PACIENTE DURANTE LAS CONSULTAS DE MEDICINA GENERAL? RESULTADOS DEL ESTUDIO INTERMEDE

 

Darlow B, Dean S, Perry M, Mathieson F, Baxter GD, Dowell A. Acute low back pain management in general practice: uncertainty and conflicting certainties. Fam Pract 2014;31:723-732 [C,I]

25192904             R/C

MANEJO DEL DOLOR LUMBAR AGUDO EN MEDICINA GENERAL: INCERTIDUMBRE Y CERTEZAS CONFLICTIVAS

 

GACETA SANITARIA 

 

López-Cepero J, Lana A, Rodríguez-Franco L, Paíno SG, Rodríguez-Díaz FJ. Percepción y etiquetado de la experiencia violenta en las relaciones de noviazgo juvenil. Gac Sanit 2015;29:21-26 [T,I]

25176129             R/C

PERCEPCIÓN Y ETIQUETADO DE LA EXPERIENCIA VIOLENTA EN LAS RELACIONES DE NOVIAZGO JUVENIL

 

Aguilar-Palacio I, Carrera-Lasfuentes P, Rabanaque MJ. Salud percibida y nivel educativo en España: tendencias por comunidades autónomas y sexo (2001-2012) Gac Sanit 2015;29:37-43 [T,I]

25127554             R/C

SALUD PERCIBIDA Y NIVEL EDUCATIVO EN ESPAÑA: TENDENCIAS POR COMUNIDADES AUTÓNOMAS Y SEXO (2001-2012)

 

López-Torres J, Rabanales J, Fernández R, López FJ, Panadés L, Romero V. Resultados de un programa de telemedicina para pacientes con diabetes tipo 2 en atención primaria. Gac Sanit 2015;29:55-58 [QE,I]

25440441             R/C

RESULTADOS DE UN PROGRAMA DE TELEMEDICINA PARA PACIENTES CON DIABETES TIPO 2 EN ATENCIÓN PRIMARIA

 

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 

 

Saini SD, van Hees F, Vijan S. Smarter screening for cancer: possibilities and challenges of personalization. JAMA 2014;312:2211-2212 [AO,I]

25461993

UN CRIBAJE MÁS INTELIGENTE DEL CÁNCER: POSIBILIDADES Y RETOS DE LA PERSONALIZACIÓN

 

Gibbons RJ. Optimal medical therapy vs CT angiography screening for patients with diabetes. JAMA 2014;312:2219-2220 [AO,I]

25402605

TRATAMIENTO MÉDICO ÓPTIMO FRENTE A CRIBAJE ANGIOGRÁFICO POR TC EN PACIENTES CON DIABETES

 

Muhlestein JB, Lappé DL, Lima JA, Rosen BD, May HT, Knight S, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA 2014;312:2234-2243 [EC,II]

25402757             R/C

EFECTO DEL CRIBAJE DE ENFERMEDAD ARTERIAL CORONARIA MEDIANTE ANGIOGRAFÍA POR TC SOBRE LA MORTALIDAD Y LOS ACONTECIMIENTOS CARDIOVASCULARES EN PACIENTES DE ALTO RIESGO CON DIABETES: ENSAYO CLÍNICO ALEATORIZADO FACTOR-64

 

Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA 2014;312:2265-2276 [M,II]

25461996             R/C

LEUCEMIA LINFOCÍTICA CRÓNICA: REVISIÓN

 

Volerman A, Cifu AS. Cervical cancer screening. JAMA 2014;312:2279-2280 [AO,I]

25461998

CRIBAJE DE CÁNCER DE CÉRVIX

 

Edmond MB, Diekema DJ, Perencevich EN. Ebola virus disease and the need for new personal protective equipment. JAMA 2014;312:2495-2496 [AO,I]

25350321

ENFERMEDAD POR VIRUS DEL ÉBOLA Y NECESIDAD DE NUEVOS EQUIPOS DE PROTECCIÓN INDIVIDUAL

 

Gaziano JM, Greenland P. When should aspirin be used for prevention of cardiovascular events? JAMA 2014;312:2503-2504 [AO,I]

25402671

¿CUÁNDO SE DEBERÍA USAR LA ASPIRINA EN LA PREVENCIÓN DE ACONTECIMIENTOS CARDIOVASCULARES?

 

Eckel RH. Role of glycemic index in the context of an overall heart-healthy diet. JAMA 2014;312:2508-2509 [AO,I]

25514301

PAPEL DEL ÍNDICE GLUCÉMICO EN EL CONTEXTO DE UNA DIETA CARDIOSALUDABLE GLOBAL

 

Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014;312:2510-2520 [EC,II]

25401325             R/C

ASPIRINA A DOSIS BAJA EN LA PREVENCIÓN PRIMARIA DE ACONTECIMIENTOS CARDIOVASCULARES EN PACIENTES JAPONESES DE 60 AÑOS O MÁS CON FACTORES DE RIESGO ATEROSCLERÓTICOS: ENSAYO CLÍNICO ALEATORIZADO

 

Sacks FM, Carey VJ, Anderson CA, Miller ER 3rd, Copeland T, Charleston J, et al. Effects of high vs low glycemic index of dietary carbohydrate on cardiovascular disease risk factors and insulin sensitivity: the OmniCarb randomized clinical trial. JAMA 2014;312:2531-2541 [EC,II]

25514303             R/C

EFECTOS DE ÍNDICES GLUCÉMICOS ALTOS FRENTE A BAJOS DE CARBOHIDRATOS EN LA DIETA SOBRE LOS FACTORES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR Y LA SENSIBILIDAD A LA INSULINA: ENSAYO CLÍNICO ALEATORIZADO OMNICARB

 

Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA 2014;312:2551-2561 [R,I]

25514304             R/C

DIAGNÓSTICO Y MANEJO DEL DETERIORO COGNITIVO LEVE: REVISIÓN CLÍNICA

 

JAMA INTERNAL MEDICINE 

 

McDonagh J. Statin-related cognitive impairment in the real world: you'll live longer, but you might not like it. JAMA Intern Med 2014;174:1889 [AO,I]

25347692

DETERIORO COGNITIVO RELACIONADO CON LAS ESTATINAS EN EL MUNDO REAL: VIVIRÁS MÁS, PERO PUEDE QUE NO TE GUSTE

 

Garin N, Genné D, Carballo S, Chuard C, Eich G, Hugli O, et al. ß-Lactam monotherapy vs ß-Lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014;174:1894-1901 [EC,I]

25286173             R/C

MONOTERAPIA CON BETA-LACTÁMICOS FRENTE A TRATAMIENTO COMBINADO BETA-LACTÁMICOS Y MACRÓLIDOS EN LA NEUMONÍA ADQUIRIDA EN LA COMUNIDAD MODERADAMENTE GRAVE: ENSAYO DE NO INFERIORIDAD ALEATORIZADO

 

Rostron BL, Chang CM, Pechacek TF. Estimation of cigarette smoking-attributable morbidity in the United States. JAMA Intern Med 2014;174:1922-1928 [T,II]

25317719             R/C

CÁLCULO DE LA MORBILIDAD ATRIBUIBLE A CONSUMO DE CIGARRILLOS EN EE UU

 

Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014;174:1930-1933 [T,II]

25329919             R/C

INFORMES DE JUEGO PATOLÓGICO, HIPERSEXUALIDAD Y COMPRAS COMPULSIVAS ASOCIADOS A FÁRMACOS AGONISTAS DE RECEPTORES DE DOPAMINA

 

Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study. JAMA Intern Med 2014;174:1964-1971 [S,II]

25285455             R/C

REFLEXIÓN POSTERIOR SOBRE LA CALCULADORA DE RIESGO CARDIOVASCULAR: PAPELES DE LAS ESTATINAS, REVASCULARIZACIONES E INFRAESTIMACIÓN EN EL ESTUDIO WOMEN'S HEALTH

 

Brett AS, Levine JD. The case against identifying carotid stenosis in asymptomatic patients. JAMA Intern Med 2014;174:2004-2008 [R,I]

25265407             R/C

EL CASO CONTRA LA IDENTIFICACIÓN DE ESTENOSIS CAROTÍDEA EN PACIENTES ASINTOMÁTICOS

 

Woolf SH, Harris RP, Campos-Outcalt D. Low-dose computed tomography screening for lung cancer: how strong is the evidence? JAMA Intern Med 2014;174:2019-2022 [AO,II]

25317533             R/C

CRIBAJE CON TC DE BAJA DOSISI PARA EL CÁNCER DE PULMÓN: ¿CUÁN FUERTE ES LA EVIDENCIA?

 

JAMA PSYCHIATRY 

 

Bryant RA, Kenny L, Joscelyne A, Rawson N, Maccallum F, Cahill C, et al. Treating prolonged grief disorder: a randomized clinical trial. JAMA Psychiatry 2014;71:1332-1339 [EC,I]

25338187             R/C

TRATAR EL DUELO PROLONGADO: ENSAYO CLÍNICO ALEATORIZADO

 

Pinto SM, Geoffroy MC, Power C. Depressive symptoms and physical activity during 3 decades in adult life: bidirectional associations in a prospective cohort study. JAMA Psychiatry 2014;71:1373-1380

[S,I]

25321867             R/C

SÍNTOMAS DEPRESIVOS Y ACTIVIDAD FÍSICA DURANTE 3 DÉCADAS EN LA VIDA ADULTA: ASOCIACIONES BIDIRECCIONALES EN UN ESTUDIO DE COHORTE PROSPECTIVO

 

Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014;71:1381-1391 [M,II]

25322082             R/C

EFECTO DEL TRATAMIENTO ANTIINFLAMATORIO SOBRE LA DEPRESIÓN, LOS SÍNTOMAS DEPRESIVOS Y EFECTOS ADVERSOS: REVISIÓN SISTEMÁTICA Y METAANÁLISIS DE ENSAYOS CLÍNICOS ALEATORIZADOS

 

MEDICINA CLINICA 

 

Posso M, Brugulat-Guiteras P, Puig T, Mompart-Penina A, Medina-Bustos A, Alcañiz M, et al. Prevalencia y condicionantes de la obesidad en la población infantojuvenil de Cataluña, 2006-2012. Med Clin (Barc) 2014;143:475-483 [T,I]

24661534             R/C

PREVALENCIA Y CONDICIONANTES DE LA OBESIDAD EN LA POBLACIÓN INFANTOJUVENIL DE CATALUÑA, 2006-2012

 

Ripollés-de Ramón J, Muñoz-Corcuera M, Bravo-Llatas C, Bascones-Martínez A. Aplicación de un gel de ácido tranexámico en pacientes tratados con anticoagulantes orales. Med Clin (Barc) 2014;143:484-488 [T,I]

24268907             R/C

APLICACIÓN DE UN GEL DE ÁCIDO TRANEXÁMICO EN PACIENTES TRATADOS CON ANTICOAGULANTES ORALES

 

Serra-Majem L. Obesidad infantil: ¿hemos tocado fondo? ¿Podemos echar las campanas al vuelo? Med Clin (Barc) 2014;143:489-491 [AO,I]

24667110

OBESIDAD INFANTIL: ¿HEMOS TOCADO FONDO? ¿PODEMOS ECHAR LAS CAMPANAS AL VUELO?

 

Tello-Montoliu A, Jover E, Valdés M. Nuevos antiagregantes plaquetarios en cardiopatía isquémica. Med Clin (Barc) 2014;143:508-514 [R,I]

24480290             R/C

NUEVOS ANTIAGREGANTES PLAQUETARIOS EN CARDIOPATÍA ISQUÉMICA

 

Calero-Paniagua I, Ruíz-Chicote AM, Nieto-Rodríguez JA, Ruiz-Ribó MD, Cortés AB. Utilidad de la cistatina C como marcador pronóstico en la enfermedad tromboembólica venosa. Med Clin (Barc) 2014;143:530-534 [S,I]

24216017             R/C

UTILIDAD DE LA CISTATINA C COMO MARCADOR PRONÓSTICO EN LA ENFERMEDAD TROMBOEMBÓLICA VENOSA

 

Ruiz-Salas A, Cortés-Rodríguez M, Alegre-Bayo N, Algarra-García J, de Teresa E, Jiménez-Navarro MF. Relación entre cistatina C y calcificación coronaria en pacientes con riesgo cardiovascular intermedio. Med Clin (Barc) 2014;143:535-538 [T,I]

24725853             R/C

RELACIÓN ENTRE CISTATINA C Y CALCIFICACIÓN CORONARIA EN PACIENTES CON RIESGO CARDIOVASCULAR INTERMEDIO

 

Miñambres I, de Leiva A, Pérez A. Hipovitaminosis D y síndrome metabólico. Med Clin (Barc) 2014;143:542-547 [R,I]

24529881             R/C

HIPOVITAMINOSIS D Y SÍNDROME METABÓLICO

 

Martín-Arribas MC, Martínez-Hervás I, Rodríguez-Lozano I, Arias-Díaz J. Percepción del fraude científico en las revistas biomédicas españolas. Med Clin (Barc) 2014;143:554-559 [R,I]

25073824

PERCEPCIÓN DEL FRAUDE CIENTÍFICO EN LAS REVISTAS BIOMÉDICAS ESPAÑOLAS

 

SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE 

 

Liira H, Engberg E, Leppävuori J, From S, Kautiainen H, Liira J, et al. Exercise intervention and health checks for middle-aged men with elevated cardiovascular risk: a randomized controlled trial. Scand J Prim Health Care 2014;32:156-162 [EC,I]

25434409             R/C

INTERVENCIÓN CON EJERCICIO Y PRUEBAS DE SALUD EN HOMBRES DE MEDIANA EDAD CON RIESGO CARDIOVASCULAR ELEVADO: ENSAYO CONTROLADO ALEATORIZADO

 

Aakhus E, Oxman AD, Flottorp SA. Determinants of adherence to recommendations for depressed elderly patients in primary care: a multi-methods study. Scand J Prim Health Care 2014;32:170-179 [C,T,I]

25431340             R/C

DETERMINANTES DE CUMPLIMIENTO DE LAS RECOMENDACIONES PARA PACIENTES ANCIANOS DEPRIMIDOS EN ATENCIÓN PRIMARIA: ESTUDIO PLURIMETODOLÓGICO

 

Lenander C, Elfsson B, Danielsson B, Midlöv P, Hasselström J. Effects of a pharmacist-led structured medication review in primary care on drug-related problems and hospital admission rates: a randomized controlled trial. Scand J Prim Health Care 2014;32:180-186 [EC,I]

25347723             R/C

EFECTOS DE UNA REVISIÓN ESTRUCTURADA DE LA MEDICACIÓN POR PARTE DEL FARMACÉUTICO EN ATENCIÓN PRIMARIA SOBRE LOS PROBLEMAS EN RELACIÓN CON LOS FÁRMACOS Y SOBRE LAS TASAS DE INGRESO EN HOSPITAL: ENSAYO CONTROLADO ALEATORIZADO

 

Jansen K, Schaufel MA, Ruths S. Drug treatment at the end of life: an epidemiologic study in nursing homes. Scand J Prim Health Care 2014;32:187-192 [S,I]

25363144             R/C

TRATAMIENTO FARMACOLÓGICO TERMINAL: ESTUDIO EPIDEMIOLÓGICO EN RESIDENCIAS

 

Hedin K, Strandberg EL, Gröndal H, Brorsson A, Thulesius H, André M. Management of patients with sore throats in relation to guidelines: an interview study in Sweden. Scand J Prim Health Care 2014;32:193-199 [C,I]

25363143             R/C

MANEJO DE LOS PACIENTES CON DOLORES DE GARGANTA EN RELACIÓN CON LAS GUÍAS: ESTUDIO MEDIANTE ENTREVISTAS EN SUECIA

 

Huibers L, Moth G, Christensen MB, Vedsted P. Antibiotic prescribing patterns in out-of-hours primary care: a population-based descriptive study. Scand J Prim Health Care 2014;32:200-207 [T,I]

25350313             R/C

PAUTAS DE PRESCRIPCIÓN DE ANTIBIÓTICOS EN ATENCIÓN CONTINUADA EN ATENCIÓN PRIMARIA: ESTUDIO DESCRIPTIVO POBLACIONAL

 

Johansson C, Hägg L, Johansson L, Jansson JH. Characterization of patients with atrial fibrillation not treated with oral anticoagulants. Scand J Prim Health Care 2014;32:226-231 [T,I]

25464863             R/C

CARACTERIZACIÓN DE LOS PACIENTES CON FIBRILACIÓN AURICULAR NO TRATADOS CON ANTICOAGULANTES ORALES

 

Diaz E, Gimeno-Feliu LA, Calderón-Larrañaga A, Prados-Torres A. Frequent attenders in general practice and immigrant status in Norway: a nationwide cross-sectional study. Scand J Prim Health Care 2014;32:232-240 [T,I]

25421090             R/C

HIPERFRECUENTADORES EN MEDICINA GENERAL Y CONDICIÓN DE INMIGRANTE EN NORUEGA: ESTUDIO TRANSVERSAL NACIONAL

 

Nilsson S, Andersson A, Janzon M, Karlsson JE, Levin LÅ. Cost consequences of point-of-care troponin T testing in a Swedish primary health care setting. Scand J Prim Health Care 2014;32:241-247 [S,I]

25434410             R/C

CONSECUENCIAS DE COSTE DE LA PRUEBA RÁPIDA DE TROPONINA T EN UN DISPOSITIVO DE ATENCIÓN PRMARIA DE SALUD SUECO

 

THE LANCET 

 

Hill MD, Coutts SB. Alteplase in acute ischaemic stroke: the need for speed. Lancet 2014;384:1904-1906 [AO,I]

25106064

ALTEPLASA EN EL ICTUS ISQUÉMICO AGUDO: NECESIDAD DE VELOCIDAD

 

Chiasson JL, Le Lorier J. Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes. Lancet 2014;384:1906-1907 [AO,I]

25088436

CONTROL GLUCÉMICO, ENFERMEDAD CARDIOVASCULAR Y MORTALIDAD EN LA DIABETES TIPO 2

 

Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 2014;384:1953-1997 [M,II]

25513438

ABORDAJE DE LA ENFERMEDAD HEPÁTICA EN R.U.: PLAN DE ACCIÓN PARA ALCANZAR LA EXCELENCIA EN LA ATENCIÓN SANITARIA Y REDUCIR LA MORTALIDAD PREMATURA A PARTIR DE CUESTIONES DE HÁBITOS COMO EL CONSUMO EXCESIVO DE ALCOHOL, OBESIDAD HEPATITITS VÍRICA

 

Roberts I, Perner A. Ebola virus disease: clinical care and patient-centred research. Lancet 2014;384:2001-2002 [AO,I]

25483156

ENFERMEDAD POR EL VIRUS DEL ÉBOLA: ATENCIÓN CLÍNICA E INVESTIGACIÓN ENFOCADA AL PACIENTE

 

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al; ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-2035 [EC,II]

25108889             R/C

CRIBAJE Y MORTALIDAD POR CÁNCER DE PRÓSTATA: RESULTADOS DEL ESTUDIO ERSPC TRAS 13 AÑOS DE SEGUIMIENTO

 

Drug labelling and pregnancy. Lancet 2014;384:2084 [AO,I]

25497185

ETIQUETADO DE MEDICAMENTOS Y EMBARAZO

 

THE NEW ENGLAND JOURNAL OF MEDICINE 

 

Colombo A, Chieffo A. Dual antiplatelet therapy after drug-eluting stents--how long to treat? N Engl J Med 2014;371:2225-2226 [AO,I]

25399657

TERAPIA ANTIPLAQUETARIA DOBLE TRAS STENTS FARMACOACTIVOS ¿DURANTE CUÁNTO TRATAR?

 

Kanapathipillai R, Henao AM, Fast P, Wood D, Dye C, Kieny MP, et al. Ebola vaccine--an urgent international priority. N Engl J Med 2014;371:2249-2251

[AO,I]

25289888

VACUNA CONTRA EL ÉBOLA--PRIORIDAD INTERNACIONAL URGENTE

 

Chin MH. How to achieve health equity. N Engl J Med 2014;371:2331-2332 [AO,I]

25494273

CÓMO CONSEGUIR LA EQUIDAD SANITARIA

 

Gonsalves G, Staley P. Panic, paranoia, and public health--the AIDS epidemic's lessons for Ebola. N Engl J Med 2014;371:2348-2349 [AO,I]

25372947

PÁNICO, PARANOIA Y SALUD PÚBLICA--LECCIONES EPIDÉMICAS DEL SIDA PARA EL ÉBOLA

 

Walker N, Howe C, Glover M, McRobbie H, Barnes J, Nosa V, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med 2014;371:2353-2362 [EC,I]

25517706             R/C

CITISINA FRENTE A NICOTINA PARA EL ABANDONO TABÁQUICO

 

Rigotti NA. Cytisine--a tobacco treatment hiding in plain sight. N Engl J Med 2014;371:2429-2430 [AO,I]

25517710

CITISINA-- TRATAMIENTO PARA EL TABACO ESCONDIDO A SIMPLE VISTA

 

THORAX 

 

Pépin JL, Timsit JF, Tamisier R, Lévy P. Is CPAP effective in reducing blood pressure in minimally symptomatic obstructive sleep apnoea? Thorax 2014;69:1068-1070 [AO,I]

25084789

¿ES EFECTIVO EL CPAP PARA REDUCIR LA PRESIÓN ARTERIAL EN LA APNEA OBSTRUCTIVA DEL SUEÑO MÍNIMAMENTE SINTOMÁTICA?

 

Halpin DM, Quint JK. The WISDOM of inhaled corticosteroids in COPD. Thorax 2014;69:1071-1072 [AO,I]

25323619

LA SABIDURÍA (WISDOM, por el estudio WISDOM) DE LOS CORTICOIDES INHALADOS EN LA EPOC

 

Bratton DJ, Stradling JR, Barbé F, Kohler M. Effect of CPAP on blood pressure in patients with minimally symptomatic obstructive sleep apnoea: a meta-analysis using individual patient data from four randomised controlled trials. Thorax 2014;69:1128-1135 [M,II]

24947425             R/C

EFECTO DEL CPAP SOBRE LA PRESIÓN ARTERIAL EN PACIENTES CON APNEA OBSTRUCTIVA DEL SUEÑO MÍNIMAMENTE SINTOMÁTICA: METAANÁLISIS USANDO DATOS INDIVIDUALES DE PACIENTES DE CUATRO ENSAYOS CONTROLADOS ALEATORIZADOS

 

 

ANNALS OF INTERNAL MEDICINE

 

S25244227  

The USPSTF recommends intensive behavioral counseling for all sexually active adolescents and for adults who are at increased risk for STIs. (B recommendation).

S25200125  

The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. (B recommendation).

S25243785  

The USPSTF recommends screening for chlamydia in sexually active females aged 24 years or younger and in older women who are at increased risk for infection. (B recommendation) The USPSTF recommends screening for gonorrhea in sexually active females aged 24 years or younger and in older women who are at increased risk for infection. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men. (I statement).

S25244000  

Chlamydia screening in young women may reduce the incidence of pelvic inflammatory disease. Nucleic acid amplification tests are accurate for diagnosing gonorrhea and chlamydia in asymptomatic persons.

 

ARCHIVOS DE BRONCONEUMOLOGIA

 

S25443591 

Nuestros datos confirman diferencias clínicas y analíticas entre una AEPOC y una NEPOC en los pacientes que precisan ingreso hospitalario, aunque sin diferencias en la evolución posterior.

S25059585 

El síndrome de apnea-hipopnea del sueño es una enfermedad muy prevalente, con tasas altas de infradiagnóstico en el momento actual, que conlleva un elevado impacto sanitario, económico y social, y consume gran parte de los recursos destinados a las terapias respiratorias domiciliarias. Con motivo del Año SEPAR 2014 del paciente crónico y las terapias respiratorias domiciliarias, patrocinado por la Sociedad Española de Neumología y Cirugía Torácica, en este artículo se revisa la literatura más reciente publicada sobre las indicaciones del tratamiento de la apnea del sueño y sus controversias, las últimas evidencias de las indicaciones de los distintos dispositivos de presión positiva, así como los modos de ajuste, desde el uso de fórmulas empíricas o estimaciones matemáticas, a los modernos equipos de auto-CPAP, pasando por la titulación manual como «gold standard». Además, se hace hincapié en la necesidad de seguimiento que los pacientes precisan para asegurar la adherencia y cumplimiento de la terapia. Por último, se comentan someramente otros tratamientos, que no son el objetivo del artículo.

 

ARTHRITIS AND RHEUMATOLOGY

 

S25185757  

Increased fat mass and fat:muscle mass ratio were significantly associated with musculoskeletal pain among women. Widespread pain was significantly associated with a high fat:muscle mass ratio after adjustment for confounders. Understanding the relationship between fat mass and pain may provide insights into preventative measures and therapeutic strategies for musculoskeletal pain.

 

ATENCION PRIMARIA

 

CATALA-LOPEZ

Las revisiones sistemáticas y los metaanálisis se han consolidado como una herramienta fundamental para la práctica clínica basada en la evidencia. Inicialmente, el metaanálisis fue propuesto como una técnica que podría mejorar la precisión y la potencia estadística de la investigación procedente de estudios individuales con pequeño tamaño muestral. Sin embargo, uno de sus principales inconvenientes es que suelen comparar no más de 2 intervenciones alternativas a la vez. Los «metaanálisis en red» utilizan técnicas novedosas de análisis que permiten incorporar la información procedente de comparaciones directas e indirectas a partir de una red de estudios que examina los efectos de diversos tratamientos de una manera más completa. Pese a sus potenciales limitaciones, su aplicación en epidemiología clínica podría ser potencialmente útil en situaciones en las que existen varios tratamientos que se han comparado frente a un comparador común.

Además, estas técnicas pueden ser relevantes ante una pregunta clínica o de investigación cuando existen múltiples tratamientos que deben ser considerados, o cuando se dispone tanto de información directa como indirecta en el cuerpo de la evidencia.

S24863857 

La prevalencia de inactividad física descendió entre 1987 y 2007, y los mayores descensos fueron en sujetos con estudios universitarios. La brecha de las diferencias en prevalencias y OR de inactividad física en tiempo libre, ha aumentado con el tiempo. Parece necesario contribuir, desde estrategias de Educación para la Salud y promoción de la equidad, a la reducción de las desigualdades en conductas de riesgo.

S24986634 

 Implementar una intervención educativa breve en AP mejora la calidad del sueño y potencia una menor prescripción de benzodiacepinas.

S24811538 

En las publicaciones de atención primaria existe gran diversidad tanto en áreas de investigación como en las revistas donde se publican. La mayoría proceden de centros de salud, tratan aspectos clínicos y se publican en revistas españolas. Se observan diferencias en el volumen de producción científica entre comunidades autónomas.

 

BRITISH JOURNAL OF PSYCHIATRY

 

S25452601 

Background Agitation in dementia is common, persistent and distressing and can lead to care breakdown. Medication is often ineffective and harmful. Aims To systematically review randomised controlled trial evidence regarding non-pharmacological interventions. Method We reviewed 33 studies fitting predetermined criteria, assessed their validity and calculated standardised effect sizes (SES). Results Person-centred care, communication skills training and adapted dementia care mapping decreased symptomatic and severe agitation in care homes immediately (SES range 0.3-1.8) and for up to 6 months afterwards (SES range 0.2-2.2). Activities and music therapy by protocol (SES range 0.5-0.6) decreased overall agitation and sensory intervention decreased clinically significant agitation immediately. Aromatherapy and light therapy did not demonstrate efficacy. Conclusions There are evidence-based strategies for care homes. Future interventions should focus on consistent and long-term implementation through staff training. Further research is needed for people living in their own homes.

S25452599 

Work-related mental health disorders are a major public health problem. Consequently, psychiatrists encounter many patients whose clinical state is profoundly affected by work conditions. Psychiatrists therefore, need training in occupational/stress medicine. This would help integrate health services for these patients, aimed at preservation of work fitness and mental health.

S25359926 

Overall, this study confirms a general relationship between the economic environment and suicide rates; however, it does not support there being a clear causal relationship between the current economic crisis and an increase in the suicide rate.

 

BRITISH MEDICAL JOURNAL

 

S25225003  

Urinary incontinence affects women of all ages. History, physical examination, and certain tests can guide specialists in diagnosing stress urinary incontinence, urgency urinary incontinence, and mixed urinary incontinence. First line management includes lifestyle and behavior modification, as well as pelvic floor strength and bladder training. Drug therapy is helpful in the treatment of urgency incontinence that does not respond to conservative measures. In addition, sacral neuromodulation, intravesical onabotulinumtoxinA injections, and posterior tibial nerve stimulation can be used in select patient populations with drug refractory urgency incontinence. Midurethral synthetic slings, including retropubic and transobturator approaches, are safe and efficacious surgical options for stress urinary incontinence and have replaced more invasive bladder neck slings that use autologous or cadaveric fascia. Despite controversy surrounding vaginal mesh for prolapse, synthetic slings for the treatment of stress urinary incontinence are considered safe and minimally invasive.

S25500116  

General practice waiting rooms contain mainly old magazines. This phenomenon relates to the disappearance of the magazines rather than to the supply of old ones. Gossipy magazines were more likely to disappear than non-gossipy ones. On the grounds of cost we advise practices to supply old copies of non-gossipy magazines. A waiting room science curriculum is urgently needed.

S25398372  

Angiotensin receptor blocker showed beneficial effects comparable with ACE inhibitors in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function. Angiotensin receptor blockers could be used as an alternative to ACE inhibitors in such patients.

S25498121 

Exaggeration in news is strongly associated with exaggeration in press releases. Improving the accuracy of academic press releases could represent a key opportunity for reducing misleading health related news.

 

 

CANADIAN MEDICAL ASSOCIATION JOURNAL

 

S25349008 

We found no significant difference in analgesic efficacy between orally administered morphine and ibuprofen. However, morphine was associated with a significantly greater number of adverse effects. Our results suggest that ibuprofen remains safe and effective for outpatient pain management in children with uncomplicated fractures.

 

CIRCULATION

 

S25378546 

-The current study indicated a U-shaped association of BMI with all-cause mortality risk among African American and white patients with type 2 diabetes. A significantly increased risk of all-cause mortality was observed among African Americans with BMI<30 kg/m2 and BMI =35 kg/m2, and among whites with BMI<25 kg/m2 and BMI =40 kg/m2 compared with patients with BMI 30-34.9 kg/m2.

S25378545 

Despite the persistence of the obesity epidemic and its contribution to development of metabolic and cardiovascular diseases, a growing number of studies have described a paradoxically longer survival (the "obesity paradox") among overweight and obese adults with and without chronic diseases.1 Whereas the obesity paradox has previously been observed among adults with chronic kidney disease, heart failure and cancer, a growing number of studies have investigated this question in the setting of diabetes. Whether the obesity paradox is present in diabetes is of particular interest given the importance of obesity in the etiology of diabetes and the development of complications. In this week's issue of Circulation, Zhao and colleagues2 report a U-shaped association between weight status and mortality among adults with diabetes whereby the lowest mortality rates are observed among adults who are overweight or obese. These findings are consistent with some,3,4 but not all,5 prior findings.

 

DIABETES CARE

 

S25414390 

A low GI diet was associated with less frequent insulin use and lower birth weight than control diets, suggesting that it is the most appropriate dietary intervention to be prescribed to patients with GDM.

S25249651 

Liraglutide provides robust enhancement of ß-cell function that is sustained over 48 weeks in early T2DM but lost upon cessation of therapy.

S25193531 

Gla-300 was as effective as Gla-100 and associated with a lower risk of hypoglycemia during the night and at any time of the day.

S25336749 

Former and current smoking was associated with a higher risk of incident type 2 diabetes compared with never smoking in men and women, independent of educational level, physical activity, alcohol consumption, and diet. Smoking may be regarded as a modifiable risk factor for type 2 diabetes, and smoking cessation should be encouraged for diabetes prevention.

S25414388 

These statistics underscore the importance of finding ways to reduce the burden of prediabetes and diabetes through prevention and treatment.

S25249652 

PHEN/TPM ER plus lifestyle modification can effectively promote weight loss and improve glycemic control as a treatment approach in obese/overweight patients with type 2 diabetes.

 

DRUGS

 

S25389049  

Dapagliflozin (Forxiga(®), Farxiga(®)) is an orally administered sodium-glucose co-transporter-2 (SGLT2) inhibitor used in the management of patients with type 2 diabetes. Dapagliflozin reduces renal glucose reabsorption by inhibiting the transporter protein SGLT2 in the renal proximal tubule, thereby increasing urinary glucose excretion and reducing blood glucose levels. Its mechanism of action is independent of insulin secretion or action; therefore, dapagliflozin provides complementary therapy when used in combination with other antihyperglycaemic drugs. This article updates an earlier review of dapagliflozin and focuses on longer-term efficacy and tolerability data (e.g. from extensions of earlier clinical trials), as well as data from studies in special patient populations (e.g. history of cardiovascular disease). Numerous well-designed clinical trials with dapagliflozin, primarily as add-on therapy for 24 weeks (but also as monotherapy or initial combination therapy), have consistently demonstrated reductions in glycosylated haemoglobin, fasting plasma glucose levels and bodyweight. Extensions of these trials show the effects are maintained over longer-term follow-up periods of ˜1-4 years and dapagliflozin is generally well tolerated. Dapagliflozin has a low risk of hypoglycaemia, although the incidence varies depending on background therapy, and genital mycotic infections (particularly in women) are the most common adverse events. Dapagliflozin is not recommended in patients with moderate or severe renal impairment. In view of its unique mechanism of action and now well-established efficacy and tolerability profile, dapagliflozin is a useful treatment option in the management of type 2 diabetes, although its effects on diabetic complications remain to be evaluated.

S25414121  

Most patients with diabetes mellitus require multiple medications to achieve glycemic goals. Considering this and the increasing incidence of type 2 diabetes worldwide, the need for effective combination therapy is pressing. Basal insulin and glucagon-like peptide 1 (GLP-1) receptor agonists are frequently used to treat type 2 diabetes. Though both classes of medication are exclusively injectable, which may cause initial hesitation from providers, evidence for their combined use is substantial. This review summarizes the theoretical benefit, supporting evidence, and implementation of a combined basal insulin-GLP-1 receptor agonist regimen. Basal insulin added to a GLP-1 receptor agonist reduces hemoglobin A1c (HbA1c) without weight gain or significantly increased hypoglycemia. A GLP-1 receptor agonist added to basal insulin reduces HbA1c and body weight. Compared with the addition of meal-time insulin to basal insulin, a GLP-1 receptor agonist produces similar or greater reduction in HbA1c, weight loss instead of weight gain, and less hypoglycemia. Gastrointestinal adverse events are common with GLP-1 receptor agonists, especially during initiation and titration. However, combination with basal insulin is not expected to augment expected adverse events that come with using a GLP-1 receptor agonist. Basal insulin can be added to a GLP-1 receptor agonist with a slow titration to target goal fasting plasma glucose. In patients starting a GLP-1 receptor agonist, the dose of basal insulin should be decreased by 20 % in patients with an HbA1c =8 %. The evidence from 15 randomized prospective studies supports the combined use of a GLP-1 receptor agonist with basal insulin in a broad range of patients with uncontrolled type 2 diabetes.

S25367717  

Subcutaneous liraglutide (Victoza(®)), a glucagon-like peptide 1 receptor agonist, is approved for the treatment of adult patients with type 2 diabetes mellitus. Once-daily liraglutide, as monotherapy or add-on therapy to other antidiabetic agents (including basal insulin), was an effective and generally well tolerated treatment in adult patients with type 2 diabetes in several well-designed phase III trials and in the real world clinical practice setting. In addition to improving glycaemic control, liraglutide had beneficial effects on bodyweight, systolic blood pressure and surrogate measures of ß-cell function in clinical trials, with these benefits maintained during long-term treatment (=2 years). Liraglutide has a convenient once-daily administration regimen, a low potential for drug-drug interactions and low propensity to cause hypoglycaemia. Thus, liraglutide continues to be a useful option for the management of type 2 diabetes. This article reviews the therapeutic use of liraglutide in adult patients with type 2 diabetes and summarizes its pharmacological properties.

S25385556  

Pramipexole, a non-ergolinic, D3-preferring dopamine agonist (DA), is well established as a treatment option for motor symptoms at all stages of Parkinson's disease (PD). It is administered orally and is available as both a three-times daily immediate-release (IR) formulation and a once-daily extended-release (ER) formulation (Mirapex(®) ER, Mirapexin(®) ER; Pexola(®) ER, Sifrol(®) ER). The two formulations are bioequivalent; the majority (>80 %) of patients can be switched overnight from pramipexole IR to ER without the need for dosage adjustment. In terms of improving activities of daily living and motor function in short-term (=33-week), double-blind studies, pramipexole ER was noninferior to pramipexole IR and significantly more effective than placebo as monotherapy in patients with early PD, and similar to pramipexole IR and significantly more effective than placebo as adjunctive therapy to levodopa in patients with advanced PD. In long-term (80-week) extensions of these trials, open-label treatment with pramipexole ER was associated with sustained symptomatic benefit. Moreover, the majority of extension participants who responded to a simple convenience questionnaire expressed a preference for once-daily over three-times daily dosing. Pramipexole ER was generally well tolerated in clinical trials; no new or unexpected safety signals were identified compared with the IR formulation. Head-to-head trials are needed in order to fully define the role of pramipexole ER relative to other once-daily formulations of DAs (oral ropinirole and transdermal rotigotine). Nonetheless, by reducing the pill burden, the ER formulation of pramipexole provides a more convenient alternative to the IR formulation; studies specifically testing whether this translates into improved patient compliance and symptom control are worthwhile.

S25352391  

Oral rifaximin 550 mg (Refero(®); Targaxan(®); Tixteller(®); Xifaxan(®)) twice daily, either alone or more commonly with medicines containing lactulose, is approved in several countries, including the UK, EU and USA, for use in adults with liver disease to reduce the recurrence of episodes of overt hepatic encephalopathy (HE). Rifaximin is a broad-spectrum antibacterial that acts locally in the gut to reduce intestinal flora, including ammonia-producing species, with hyperammonaemia considered to play a central role in the pathogenesis of HE. In a 6-month, multinational trial in patients with liver disease, rifaximin 550 mg twice daily (± lactulose) was an effective and well tolerated treatment for reducing the recurrence of HE episodes. At study end, rifaximin therapy significantly prolonged the time to the first breakthrough HE episode compared with placebo (± lactulose), irrespective of geographical region or baseline patient and disease characteristics. Rifaximin treatment also significantly reduced HE-related hospitalizations and improved health-related quality of life compared with placebo. Furthermore, the efficacy of rifaximin with or without lactulose in reducing the recurrence of overt HE episodes was maintained after up to 2.5 years of treatment, with no new safety signals arising during this period. This article reviews the pharmacology and therapeutic efficacy of rifaximin 550 mg twice daily in reducing the recurrence of overt HE episodes in adults with liver disease.

S25414119  

The mitogen-activated protein kinase kinases (MAPKK) MEK1 and MEK2 are integral members of the MAPK/ERK signaling pathway and are of interest in the development of anti-cancer therapeutics. The MAPK/ERK pathway is dysregulated in more than 30 % of cancers, predominately by mutations in RAS and BRAF proteins, and MEK serves as a potential downstream target for both of these. The biology of MEK inhibition is complex, as the molecule is differentially regulated by upstream RAS or RAF. This has impacted on the past development of MEK inhibitors as treatments for cancer and may be exploited in more rational, molecularly selected drug development plans in the future. The role of MEK in cancer and the mechanism of action of MEK inhibitors is reviewed. Furthermore, MEK inhibitors that are available in standard practice, as well as those most advanced in clinical development, are discussed. Finally, next steps in the development of MEK inhibitors are considered.

 

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

 

S24813928 

Una elevada proporción de tratamientos antibióticos son susceptibles de modificación, generalmente hacia la simplificación. La adherencia a las recomendaciones fue elevada, aunque variable, dependiendo del centro, del tipo de recomendación, del periodo del estudio y de que la recomendación se realizara mediante un comentario verbal además de escrito.

S25023372 

Este artículo pretende realizar una breve revisión de los principales conceptos en los que se basan las medidas de prevención y control de la infección. La antisepsia comprende el conjunto de técnicas destinadas a la eliminación total (esterilización) o mayoritaria (desinfección) de los gérmenes que contaminan un medio. Ambos procedimientos deben ir precedidos de una limpieza del medio donde se vayan a aplicar.

La desinfección se lleva a cabo por medio de biocidas o germicidas, sustancias químicas antimicrobianas cuyos mecanismos de acción y resistencia son muy similares a los de los antibióticos. Esta similitud está generando inquietud por la posibilidad de cruce de información genética que agrave el problema de las resistencias bacterianas. La mayoría de los biocidas pueden actuar como antisépticos, aplicados sobre piel y tejidos, o desinfectantes, sobre materiales inanimados. El espectro de acción de los germicidas depende de las características propias del producto y de factores externos controlables: temperatura, concentración, tiempo de exposición, etc.

Las técnicas de esterilización son fundamentalmente de carácter físico, a través de autoclaves que exponen el material a vapor o gas esterilizante. Los mayores avances están en las exposiciones a bajas temperaturas con tiempos más cortos de exposición, en paralelo con los avances tecnológicos de instrumentación con materiales que no soportan temperaturas elevadas y con rotaciones de uso altas, por la presión asistencial.

 

EUROPEAN HEART JOURNAL

 

S24497346  

The prevalence of masked suboptimal BP control in patients with treated and well-controlled clinic BP is high. Clinic BP monitoring alone is thus inadequate to optimize BP control because many patients have an elevated nocturnal BP. These findings suggest that ABPM should become more routine to confirm BP control, especially in higher risk groups and/or those with borderline control of clinic BP.

S25265973  

Despite evidence-based interventions, coronary heart disease (CHD) remains a leading cause of global mortality. As therapies advance, patient non-adherence to established treatments is well recognized. Non-adherence is a powerful confounder of evidence-based practice and can affect daily patient management, resulting in inappropriate therapeutic escalation with greater costs and potential for harm. Moreover, it increases risk for adverse cardiac events, including mortality. Yet, non-adherence is complex, remains difficult to define, and provider ability to identify its presence accurately remains limited. Improved screening tools are needed to detect at-risk patients, enabling appropriate targeting of interventions. Given the rapidly expanding global population with CHD and emerging clinical and cost-benefits of adherence, addressing non-adherence to prescribed therapies is a top priority.

 

FAMILY PRACTICE

 

S25208544 

In patients presenting with transient or minor neurological symptoms, calculation of ACVR did not improve diagnostic accuracy for TIAMS beyond that of age and sex.

S25192904 

GPs' initial focus upon tissue injury during acute care, and providing a diagnostic label, may influence patients' subsequent alignment with a biomedical perspective and contribute to consultation conflict and patients' perception of blame when discussion of psychosocial influences is introduced. Demonstrating the relevance of the biopsychosocial model to acute LBP may improve GPs' alignment with guidelines, improve their confidence to manage these patients and ultimately improve outcomes.

S25208543 

Spontaneous idiopathic facial nerve (Bell's) palsy leaves residual hemifacial weakness in 29% which is severe and disfiguring in over half of these cases. Acute medical management remains the best way to improve outcomes. Reconstructive surgery can improve long term disfigurement. However, acute and surgical options are time-dependent. As family practitioners see, on average, one case every 2 years, a summary of this condition based on common clinical questions may improve acute management and guide referral for those who need specialist input. We formulated a series of clinical questions likely to be of use to family practitioners on encountering this condition and sought evidence from the literature to answer them. The lifetime risk is 1 in 60, and is more common in pregnancy and diabetes mellitus. Patients often present with facial pain or paraesthesia, altered taste and intolerance to loud noise in addition to facial droop. It is probably caused by ischaemic compression of the facial nerve within the meatal segment of the facial canal probably as a result of viral inflammation. When given early, high dose corticosteroids can improve outcomes. Neither antiviral therapy nor other adjuvant therapies are supported by evidence. As the facial muscles remain viable re-innervation targets for up to 2 years, late referrals require more complex reconstructions. Early recognition, steroid therapy and early referral for facial reanimation (when the diagnosis is secure) are important features of good management when encountering these complex cases.

S25214508 

Patient-doctor gender concordance/discordance is associated with their agreement/disagreement on advice given during the consultation. Physicians need to be conscious that their own demographic characteristics and perceptions might influence the quality of prevention counseling delivered to their patients.

S25298510 

Behavioural weight loss interventions in primary care yield very small reductions in body weight, which are unlikely to be clinically significant. More effective management strategies are needed for the treatment of overweight and obesity.

S25192902 

Very few studies have investigated associations between specific multimorbidity and multi-drug therapy, and most currently focus on chronic disease comorbid depression outcomes. Further research needs to identify this area as key priority for older populations who are prescribed high levels of multiple drug therapy.

S25192903 

Discontinuation of PPIs is feasible in a clinical setting, and a substantial number of the patients treated without a clear indication can safely reduce or discontinue treatment. Tapering seems to be the most effective way of doing this.

 

GACETA SANITARIA

 

S25176129 

Varones y mujeres se enfrentan a violencia de pareja durante el noviazgo de forma diferente, y sería necesario disponer de recursos para atenderlos de manera específica. Incluir preguntas sobre la sensación de atrapamiento podría contribuir a detectar precozmente la violencia de pareja. Formas de violencia sutiles, como la coerción, deberían tenerse más en cuenta en las campañas de sensibilización.

S25440441 

Aunque no se ha observado una mejoría en el control glucémico a lo largo del seguimiento, la transmisión electrónica de la información ha resultado viable y satisfactoria para los pacientes, en quienes se ha comprobado un mayor nivel de salud percibida.

S25127554 

En España existen diferencias en la prevalencia de mala salud percibida por CC.AA. Aunque no varía en el periodo analizado, se observan desigualdades en su evolución según el nivel educativo y el sexo, que podrían conllevar un aumento de las desigualdades en mujeres según el nivel educativo.

 

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

 

S25461996  

Chemoimmunotherapy is the standard first-line option approach for CLL, the most common leukemia observed in adults. Treatment is initiated when the disease becomes symptomatic, and survival is high following treatment.

S25402757  

Among asymptomatic patients with type 1 or type 2 diabetes, use of CCTA to screen for CAD did not reduce the composite rate of all-cause mortality, nonfatal MI, or unstable angina requiring hospitalization at 4 years. These findings do not support CCTA screening in this population.

S25514303  

In this 5-week controlled feeding study, diets with low glycemic index of dietary carbohydrate, compared with high glycemic index of dietary carbohydrate, did not result in improvements in insulin sensitivity, lipid levels, or systolic blood pressure. In the context of an overall DASH-type diet, using glycemic index to select specific foods may not improve cardiovascular risk factors or insulin resistance.

S25401325  

Once-daily, low-dose aspirin did not significantly reduce the risk of the composite outcome of cardiovascular death, nonfatal stroke, and nonfatal myocardial infarction among Japanese patients 60 years or older with atherosclerotic risk factors.

S25514304  

Cognitive decline and MCI have important implications for patients and their families and will require that primary care clinicians be skilled in identifying and managing this common disorder as the number of older adults increases in coming decades. Current evidence supports aerobic exercise, mental activity, and cardiovascular risk factor control in patients with MCI.

 

JAMA INTERNAL MEDICINE

 

S25285455 

Statin use, revascularization procedures, and underascertainment of events do not explain the discrepancy between observed rates of ASCVD in the WHS and those predicted by the ACC/AHA pooled cohort equations. Other explanations include changing patterns of risk within more contemporary populations.

S25317719  

We estimate that US adults have had approximately 14 million major medical conditions that were attributable to smoking. This figure is generally conservative owing to the existence of other diseases and medical events that were not included in these estimates. Cigarette smoking remains a leading cause of preventable disease in the United States, underscoring the need for continuing and vigorous smoking-prevention efforts.

S25317533 

In 2013, the US Preventive Services Task Force (USPSTF) recommended low-dose computed tomographic (CT) screening for high-risk current and former smokers with a B recommendation (indicating a level of certainty that it offered moderate to substantial net benefit). Under the Affordable Care Act, the USPSTF recommendation requires commercial insurers to fully cover low-dose CT. The Centers for Medicare & Medicaid Services (CMS) is now considering whether to also offer coverage for Medicare beneficiaries. Although the National Lung Screening Trial (NLST) demonstrated the efficacy of low-dose CT, implementation of national screening may be premature. The magnitude of benefit from routine screening is uncertain; estimates are based on data from a single study and simulation models commissioned by the USPSTF. The potential harms-which could affect a large population-include false-positive results, anxiety, radiation exposure, diagnostic workups, and the resulting complications. It is unclear if routine screening would result in net benefit or net harm. The NLST may not be generalizable to a national screening program for the Medicare age group because 73% of NLST participants were younger than 65 years. Moreover, screening outside of trial conditions is less likely to be restricted to high-risk smokers and qualified imaging centers with responsible referral protocols. Until better data are available for older adults who are screened in ordinary (nontrial) community settings, CMS should postpone coverage of low-dose CT screening for Medicare beneficiaries.

S25329919  

Our findings confirm and extend the evidence that dopamine receptor agonist drugs are associated with these specific impulse control disorders. At present, none of the dopamine receptor agonist drugs approved by the FDA have boxed warnings as part of their prescribing information. Our data, and data from prior studies, show the need for more prominent warnings.

S25265407  

Carotid ultrasonography is performed frequently to identify carotid stenosis in patients with no history of carotid-territory cerebrovascular ischemia. The premises of such testing are that the potential benefit of endarterectomy or stenting exceeds the potential harm in patients with asymptomatic stenosis and that discovery of asymptomatic stenosis may trigger beneficial changes in lifestyle or medical management that otherwise would not have occurred. However, given low contemporary rates of stroke in medically managed patients with asymptomatic carotid stenosis, invasive carotid procedures cannot be justified in this population. Moreover, among patients at increased cardiovascular risk, there is no evidence that carotid imaging motivates behavioral change or improves risk stratification beyond consideration of conventional risk factors. In this focused review, we address topics that should help health care professionals advise patients who inquire about carotid screening and patients in whom asymptomatic carotid stenosis has already been identified. We conclude that there is currently no role for carotid imaging in patients without a history of carotid-territory stroke or transient ischemic attack.

S25286173  

We did not find noninferiority of ß-lactam monotherapy in patients hospitalized for moderately severe community-acquired pneumonia. Patients infected with atypical pathogens or with PSI category IV pneumonia had delayed clinical stability with monotherapy.

 

JAMA PSYCHIATRY

 

S25321867  

The relationship between activity and depressive symptoms was bidirectional, albeit more persistent during adult life in the direction from activity to depressive symptoms. Findings suggest that activity may alleviate depressive symptoms in the general population and, in turn, depressive symptoms in early adulthood may be a barrier to activity.

S25322082  

Our analysis suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms without increased risks of adverse effects. However, a high risk of bias and high heterogeneity made the mean estimate uncertain. This study supports a proof-of-concept concerning the use of anti-inflammatory treatment in depression. Identification of subgroups that could benefit from such treatment might be warranted.

S25338187  

Including exposure therapy that promotes emotional processing of memories of the death is an important component to achieve optimal reductions in PGD severity. Facilitating emotional responses to the death may promote greater changes in appraisals about the loss, which are associated with symptom reduction. Promotion of emotional processing techniques in therapies to treat patients with PGD is needed.

 

MEDICINA CLINICA

 

S24268907 

La aplicación del ácido tranexámico en gel (Kin Exogel) en pacientes en tratamiento con anticoagulantes orales favorece el grado de cicatrización y la coagulación en las primeras 48-72 h.

S24529881 

El síndrome metabólico y la hipovitaminosis D constituyen 2 trastornos con elevada prevalencia que comparten diversos factores de riesgo y existen amplias evidencias epidemiológicas que los relacionan. Aunque los mecanismos implicados en esta asociación no están bien establecidos, se ha relacionado la hipovitaminosis D con la resistencia a la insulina, la disminución en la secreción de insulina o la activación del sistema renina-angiotensina, mecanismos implicados en la fisiopatología del síndrome metabólico. Sin embargo, la aparente ineficacia de la suplementación con vitamina D sobre los componentes del síndrome metabólico, así como la escasa información acerca del efecto de la mejoría del control de los componentes del síndrome metabólico sobre las concentraciones de vitamina, no permiten establecer los mecanismos ni la dirección de la relación causal entre estas 2 afecciones. En general, por la alta prevalencia y la asociación epidemiológica de ambos procesos, podría considerarse la hipovitaminosis D un componente más del síndrome metabólico.

S24480290 

El doble tratamiento antiagregante con ácido acetilsalicílico y clopidogrel reduce considerablemente las complicaciones trombóticas de las fases aguda y crónica en la cardiopatía isquémica. Pese al buen cumplimiento terapéutico, un porcentaje no despreciable de pacientes continúa presentando episodios adversos. Por ello, nuevos compuestos farmacológicamente más favorables están ya disponibles clínicamente (como es el caso de prasugrel y ticagrelor) o en fases avanzadas de su desarrollo. La presente revisión tiene como objetivo principal la descripción de los nuevos fármacos antiagregantes, en especial prasugrel y ticagrelor.

S24661534 

La obesidad y el sobrepeso en la población infantojuvenil catalana se han mantenido estables durante 2006-2012, siendo de las más altas de Europa. Para afrontar este importante problema de salud pública, es necesario un enfoque integral e interdisciplinario que considere tanto los determinantes sociales como los estilos de vida del entorno infantil.

S24725853 

Los valores de CTC podrían asociarse con el CAC y con el riesgo de enfermedad coronaria. Es necesaria la aparición de nuevos estudios para conocer la importancia de estos marcadores en la práctica clínica habitual.

S24216017 

La concentración de cisC en el momento del diagnóstico de los pacientes con ETEV tiene valor pronóstico, similar al de creatinina sérica e inferior al del NT-proBNP.

 

SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE

 

S25464863  

Among patients with AF without OAC treatment a reason could be identified to withhold OAC in 75%. The underuse of OAC is estimated to be 25%.

S25350313  

Antibiotics were most often prescribed in clinic consultations, but, in absolute terms, many were also prescribed by telephone. The high prescription proportion, particularly antibacterial eye drops for young infants, suggests room for improvement in rational antibiotic use.

S25434410  

The use of POCT-TnT in primary care may be cost saving but at the expense of missed cases.

S25431340  

A total of 352 determinants were identified, of which 99 were prioritized. The most frequently identified factors had to do with dissemination of guidelines, general practitioners' time constraints, the low prioritization of elderly patients with depression, and the patients' or relatives' wish for medication. Approximately three-quarters of the determinants were from three of the seven domains in the generic checklist: individual healthcare professional factors, patient factors, and incentives and resources. The survey did not provide useful information due to a low response rate and a lack of responses to open-ended questions. Implications. The list of prioritized determinants can inform the design of interventions to implement recommendations for elderly patients with depression. The importance of the determinants that were identified may vary across communities, practices. and patients. Interventions that address important determinants are necessary to improve practice.

S25363144  

Palliative drug therapy and drug therapy changes are common for nursing home patients on the last day of life. Improvements in end-of-life care in nursing homes imply addressing prognostication and earlier response to palliative needs.

S25347723  

The addition of a skilled pharmacist to the primary care team may contribute to reductions in numbers of drugs and maintenance of self-rated health in elderly patients with polypharmacy.

S25434409  

Physical activity increased in all study groups of middle-aged men in this health-promotion trial. The interventions had no effect on metabolic syndrome or other cardiovascular outcomes in the participants. The trial increased awareness and collaboration in physical activity promotion among municipal health care and exercise services.

S25421090  

Although immigrants account for a small percentage of all FAs, GPs and policy-makers should be aware of differences in socioeconomic and morbidity profiles to provide equality of health care.

S25363143  

This interview study of sore throat management in a strategically sampled group of Swedish GPs showed that while two-thirds were non-adherent and had a liberal attitude to antibiotics one-third were guideline adherent with a restricted view on antibiotics. Non-adherent GPs revealed significant knowledge gaps. Adherent GPs had discussed guidelines within the primary care team while non-adherent GPs had not. Guideline implementation thus seemed to be promoted by knowledge shared in team discussions.

 

THE LANCET

 

S25108889  

In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings after 9 and 11 years. Despite our findings, further quantification of harms and their reduction are still considered a prerequisite for the introduction of populated-based screening.

 

THE NEW ENGLAND JOURNAL OF MEDICINE

 

S25517706  

When combined with brief behavioral support, cytisine was found to be superior to nicotine-replacement therapy in helping smokers quit smoking, but it was associated with a higher frequency of self-reported adverse events. (Funded by the Health Research Council of New Zealand; Australian New Zealand Clinical Trials Registry number, ACTRN12610000590066.).

 

THORAX

 

S24947425 

Although CPAP treatment reduces OSA severity and sleepiness, it seems not to have a beneficial effect on BP in patients with minimally symptomatic OSA, except in patients who used CPAP for >4 h/night.

 

 

 

 

 

 

 

                      

XXVIII Congreso de Comunicación y Salud

 

 

21 Jor. Residentes y Tutores semFYC

 


____________________________

 Para pacientes
@pontealdiaAP
 @pontealdiaURG
55 e.SAMFyC

 


 

semFYC
 

 

Estadisticas

Ver contenido por hits : 1055870



La SAMFyC:
 C/ Arriola, 4, bajo D, CP.18001 - Granada. Email: samfyc@samfyc.es; Teléfono: 958 804 201 - Fax: 958 804 202. Horario de invierno: lunes a jueves de 9:00 a 17:30 horas; viernes de 9:00 a 14:30 horas. Horario de verano: lunes a viernes de 8:00 a 15:00h. Todos los derechos reservados. Aviso Legal. 


¡CSS Válido!

Diseño web